• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高级别浆液性卵巢癌中p53免疫组织化学与突变类型不匹配

p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer.

作者信息

Park Eunhyang, Han Hyunho, Choi Sung-Eun, Park Hyunjin, Woo Ha-Young, Jang Mi, Shim Hyo-Sup, Hwang Sohyun, Kang Haeyoun, Cho Nam-Hoon

机构信息

Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Korea.

Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Korea.

出版信息

Diagnostics (Basel). 2022 Feb 24;12(3):579. doi: 10.3390/diagnostics12030579.

DOI:10.3390/diagnostics12030579
PMID:35328131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8947437/
Abstract

High-grade serous carcinoma (HGSCa) of the ovary is featured by gene mutation. Missense or nonsense mutation types accompany most cases of HGSCa that correlate well with immunohistochemical (IHC) staining results-an all (missense) or none (nonsense) pattern. However, some IHCs produce subclonal or mosaic patterns from which TP53 mutation types, including the wild type of the gene, cannot be clearly deduced. We analyzed a total of 236 cases of ovarian HGSCa and tumors of other histology by matching the results of p53 IHC staining and targeted next-generation sequencing (TruSight Tumor 170 panel). Ambiguous IHCs that do not belong to the conventional "all or none" groups were reviewed to distinguish the true wild type (WT) from potentially pathogenic subclonal or mosaic patterns. There were about 9% of sequencing-IHC mismatching cases, which were enriched by the p53 c-terminal encoding nuclear localization signal and oligomerization domain, in which the subcellular locations of p53 protein were affected. Indeed, mutations in the oligomerization domain of the p53 protein frequently revealed an unmatched signal or cytosolic staining (L289Ffs57 (Ins), and R342). We conclude that both mutation types and IHC patterns of p53 are important sources of information to provide a precise diagnosis of HGSCa.

摘要

卵巢高级别浆液性癌(HGSCa)以基因突变为特征。错义或无义突变类型伴随大多数HGSCa病例,这与免疫组化(IHC)染色结果密切相关——全(错义)或无(无义)模式。然而,一些免疫组化产生亚克隆或镶嵌模式,从中无法明确推断TP53突变类型,包括该基因的野生型。我们通过匹配p53免疫组化染色结果和靶向二代测序(TruSight肿瘤170检测板)分析了总共236例卵巢HGSCa和其他组织学肿瘤。对不属于传统“全或无”组的模糊免疫组化结果进行了审查,以区分真正的野生型(WT)与潜在致病性亚克隆或镶嵌模式。约有9%的测序-免疫组化不匹配病例,这些病例在p53编码核定位信号和寡聚化结构域的c末端富集,其中p53蛋白的亚细胞定位受到影响。事实上,p53蛋白寡聚化结构域的突变经常显示出不匹配信号或胞质染色(L289Ffs57(插入)和R342)。我们得出结论,p53的突变类型和免疫组化模式都是为HGSCa提供精确诊断的重要信息来源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/b4259c63f376/diagnostics-12-00579-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/0210ba58b45e/diagnostics-12-00579-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/bdd56b47fb69/diagnostics-12-00579-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/67a58bc5cd88/diagnostics-12-00579-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/e3e267b9d061/diagnostics-12-00579-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/2a255a348d19/diagnostics-12-00579-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/edf0f51ad6fb/diagnostics-12-00579-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/b4259c63f376/diagnostics-12-00579-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/0210ba58b45e/diagnostics-12-00579-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/bdd56b47fb69/diagnostics-12-00579-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/67a58bc5cd88/diagnostics-12-00579-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/e3e267b9d061/diagnostics-12-00579-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/2a255a348d19/diagnostics-12-00579-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/edf0f51ad6fb/diagnostics-12-00579-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5180/8947437/b4259c63f376/diagnostics-12-00579-g007.jpg

相似文献

1
p53 Immunohistochemistry and Mutation Types Mismatching in High-Grade Serous Ovarian Cancer.高级别浆液性卵巢癌中p53免疫组织化学与突变类型不匹配
Diagnostics (Basel). 2022 Feb 24;12(3):579. doi: 10.3390/diagnostics12030579.
2
Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.卵巢浆液性癌伴高级别和低级别浆液性癌混合形态学特征的临床病理、免疫组织化学和分子特征。
Am J Surg Pathol. 2020 Mar;44(3):316-328. doi: 10.1097/PAS.0000000000001419.
3
Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.高级别子宫内膜癌中 p53 免疫组化模式与下一代测序 TP53 基因突变状态的相关性评估。
Int J Gynecol Pathol. 2023 Nov 1;42(6):567-575. doi: 10.1097/PGP.0000000000000930. Epub 2022 Nov 15.
4
Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma.优化的p53免疫组化是卵巢癌突变的准确预测指标。
J Pathol Clin Res. 2016 Jul 13;2(4):247-258. doi: 10.1002/cjp2.53. eCollection 2016 Oct.
5
Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern.具有野生型p53免疫染色模式的输卵管卵巢和腹膜高级别浆液性癌的突变状态
Anticancer Res. 2017 Dec;37(12):6697-6703. doi: 10.21873/anticanres.12128.
6
The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.p53 免疫组化在妇科病理学中的多种用途:2020 年美国病理学家协会年会伴随协会会议的 ISGyP 会议记录。
Int J Gynecol Pathol. 2021 Jan;40(1):32-40. doi: 10.1097/PGP.0000000000000725.
7
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.利用免疫组织化学和大规模平行测序评估原发性高级别浆液性卵巢癌中的突变型p53
Sci Rep. 2016 May 18;6:26191. doi: 10.1038/srep26191.
8
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions.浆液性输卵管上皮内癌和同期盆腔高级别浆液性癌中的 TP53 突变——支持两种病变克隆关系的证据。
J Pathol. 2012 Feb;226(3):421-6. doi: 10.1002/path.3023. Epub 2011 Dec 23.
9
Targeted Genomic Sequencing Reveals Novel In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.靶向基因组测序揭示导致高级别浆液性输卵管卵巢癌中p53过表达的新型框内缺失突变。
Anticancer Res. 2019 Jun;39(6):2883-2889. doi: 10.21873/anticanres.13417.
10
Clinical outcomes of immunohistochemistry of the p53 Staining pattern in high-grade serous ovarian carcinoma.高级别浆液性卵巢癌中p53染色模式免疫组化的临床结果
Obstet Gynecol Sci. 2022 Sep;65(5):459-467. doi: 10.5468/ogs.22102. Epub 2022 Jul 29.

引用本文的文献

1
SOX17 expression in ovarian clear cell carcinoma.SOX17 在卵巢透明细胞癌中的表达。
J Ovarian Res. 2024 Nov 11;17(1):221. doi: 10.1186/s13048-024-01549-3.
2
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.接受一线化疗联合贝伐单抗治疗的卵巢癌患者的TP53突变与生存情况:MITO16A/MaNGO OV-2研究结果
Int J Cancer. 2025 Mar 1;156(5):1085-1096. doi: 10.1002/ijc.35203. Epub 2024 Oct 16.
3
Immunohistochemistry Markers in Ovarian and Fallopian Tube Neoplasms: a Comprehensive Review.

本文引用的文献

1
The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.p53 免疫组化在妇科病理学中的多种用途:2020 年美国病理学家协会年会伴随协会会议的 ISGyP 会议记录。
Int J Gynecol Pathol. 2021 Jan;40(1):32-40. doi: 10.1097/PGP.0000000000000725.
2
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.BRCA1/2 种系和体细胞突变景观在高级别浆液性卵巢癌患者中的分析。
BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
3
p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
卵巢和输卵管肿瘤中的免疫组织化学标志物:综述
Indian J Surg Oncol. 2024 Sep;15(Suppl 3):465-480. doi: 10.1007/s13193-024-02049-y. Epub 2024 Jul 25.
4
Predictive value of RNAscope hybridization and p53 immunohistochemistry for mutational status in canine diffuse large B-cell lymphoma.RNAscope杂交和p53免疫组织化学对犬弥漫性大B细胞淋巴瘤突变状态的预测价值
Vet Q. 2024 Dec;44(1):1-9. doi: 10.1080/01652176.2024.2403453. Epub 2024 Sep 16.
5
Diagnostic Usefulness of p53 Immunostaining in Gastric Cancer and Dysplasia: A Real-world Clinical Experience.p53 免疫组化在胃癌及其异型增生中的诊断价值:真实世界的临床经验。
In Vivo. 2024 Jul-Aug;38(4):1865-1874. doi: 10.21873/invivo.13641.
6
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations.不同解剖部位的输卵管卵巢癌肉瘤的分子特征。
Virchows Arch. 2024 Dec;485(6):1053-1061. doi: 10.1007/s00428-024-03821-9. Epub 2024 May 11.
7
TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.TP53 突变与高级别浆液性卵巢癌铂类耐药的相关性。
Gynecol Oncol. 2024 Jul;186:26-34. doi: 10.1016/j.ygyno.2024.03.023. Epub 2024 Mar 30.
8
Angio-Long Noncoding RNA MALAT1 (rs3200401) and MIAT (rs1061540) Gene Variants in Ovarian Cancer.卵巢癌中的血管长链非编码RNA MALAT1(rs3200401)和MIAT(rs1061540)基因变异
Epigenomes. 2024 Jan 29;8(1):5. doi: 10.3390/epigenomes8010005.
9
Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization.肺腺癌伴孤立性 TP53 突变:全面的临床、细胞病理学和分子特征。
Cancer Med. 2024 Jan;13(1):e6873. doi: 10.1002/cam4.6873. Epub 2024 Jan 2.
10
Recurrent Oropharyngeal Squamous Cell Carcinomas Maintain Anti-tumor Immunity and Multinucleation Levels Following Completion of Radiation.复发性口咽鳞状细胞癌在完成放疗后仍保持抗肿瘤免疫和多核水平。
Head Neck Pathol. 2023 Dec;17(4):952-960. doi: 10.1007/s12105-023-01597-z. Epub 2023 Nov 23.
p53 免疫组化是子宫内膜癌活检中 TP53 基因突变分析的准确替代指标。
J Pathol. 2020 Mar;250(3):336-345. doi: 10.1002/path.5375. Epub 2020 Jan 29.
4
Targeted Genomic Sequencing Reveals Novel In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.靶向基因组测序揭示导致高级别浆液性输卵管卵巢癌中p53过表达的新型框内缺失突变。
Anticancer Res. 2019 Jun;39(6):2883-2889. doi: 10.21873/anticanres.13417.
5
Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.BRCA 基因突变状态对晚期高级别浆液性卵巢癌生存结局的影响。
J Ovarian Res. 2019 May 7;12(1):40. doi: 10.1186/s13048-019-0511-7.
6
High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.高级别浆液性卵巢癌:BRCA突变状态、CT成像表型与临床结局之间的关联
Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.
7
Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of Missense Mutation in Prostate Cancer.用于检测前列腺癌错义突变的p53免疫组化分析、分析前及临床验证
Clin Cancer Res. 2017 Aug 15;23(16):4693-4703. doi: 10.1158/1078-0432.CCR-17-0257. Epub 2017 Apr 26.
8
p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.p53免疫组化在膀胱高级别尿路上皮癌中具有预后意义。
Histopathology. 2017 Aug;71(2):296-304. doi: 10.1111/his.13225. Epub 2017 May 22.
9
Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice.临床实践中变异体验证、质量控制及报告的推荐指南。
Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179.
10
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.癌症序列变异解读与报告的标准和指南:分子病理学协会、美国临床肿瘤学会和美国病理学家学会联合共识推荐
J Mol Diagn. 2017 Jan;19(1):4-23. doi: 10.1016/j.jmoldx.2016.10.002.